Ocular Therapeutix Inc
NASDAQ:OCUL
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
US |
Ocular Therapeutix Inc
NASDAQ:OCUL
|
965.4m USD | -9.2 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -40 845 137.7 | |
US |
Eli Lilly and Co
NYSE:LLY
|
765.1B USD | 214.5 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 83.9 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 2 143.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
364.3B USD | 48.9 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.1B USD | 24 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
192.3B GBP | 31.7 | ||
CH |
Roche Holding AG
SIX:ROG
|
188B CHF | 18.8 | ||
CH |
Novartis AG
SIX:NOVN
|
183.3B CHF | 25.5 | ||
US |
Pfizer Inc
NYSE:PFE
|
161.1B USD | 4.2 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.